A retrospective,observational study to evaluate outcomes of combination therapies of dabrafenib and trametinib or ipilimumab and nivolumab in patients with malignant melanoma
Latest Information Update: 30 Jun 2017
Price :
$35 *
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary) ; Ipilimumab; Nivolumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- 30 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology